Indicators of oxidative stress, inflammation, and endothelial dysfunction in patients with coronary atherosclerosis while taking statins
https://doi.org/10.33667/2078-5631-2020-2-29-31
Abstract
The aim of the study was to study the changes in clinical and biochemical parameters in patients with different severity of coronary atherosclerosis, depending on the administration of lipid‑lowering therapy. The study included 354 patients with coronary heart disease. All patients underwent coronary angiography with the calculation of the Gensini index. Patients were determined the level of oxidative modification of proteins, RF‑reactive protein, homocysteine and superoxide dismutase activity depending on the administration of lipid‑lowering therapy (statins). A statistical relationship between the group of patients divided by the Gensini index and statin intake was revealed. In the assessment of clinical and anthropometric indicators, significant differences in BMI, waist circumference, systolic blood pressure level were established. In assessing the lipid profile revealed significant differences between the study groups in the level of total cholesterol and the level of HDL‑cholesterol. Low adherence to lipid‑lowering therapy was noted in patients with hemodynamically significant coronary atherosclerosis. In this regard, it remains necessary to search for residual risk markers, taking into account the importance of non‑lipid risk factors.
About the Authors
Yu. A. KotovaRussian Federation
Voronezh
A. A. Zuykova
Russian Federation
Voronezh
A. N. Pashkov
Russian Federation
Voronezh
N. V. Strakhova
Russian Federation
Voronezh
O. N. Krasnorutskaya
Russian Federation
Voronezh
References
1. Рагино Ю. И., Чернявский А. М., Еременко Н. В., Шахтшнейдер Е. В., Полонская Я. В., Цымбал С. Ю., Иванова М. В., Воевода М. И. Ключевые лабораторно-диагностические биомаркеры коронарного атеросклероза. Кардиология. 2011; 3: 42–46.
2. Верткин А. Л. Проблема гипергомоцистеинемии у кардиологических больных / А. Л. Верткин, А. В. Тополянский. Фарматека. 2007; 15: 10–14.
3. Kotova Ju.A., Zuikova A. A., Pashkov A. N., Strahova N. V., Krasnorutskaya O. N. Markers of oxidative stress in patients with coronary heart disease // International journal of biomedicine. 2018; 2: 115–117.
4. Qurratu AM, Muhd Faizan ASh, Noor Akmal ShI, Azmee MGh, Rosli MA, Ika Faizura M. Nor, Mohd ZD, Wan ZWN. Oxidative status and reduced glutathione levels in premature coronary artery disease and coronary artery disease. Free Radical Research. 2017; 51: 9–10, 787–798. DOI: 10.1080/10715762.2017.1379602.
5. Tian J., Gu X., Sun Y., et al. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord. 2012; 12: 70.
6. Диагностика и коррекция липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, V пересмотр. РКЖ. 2017; 4: 5–22.
7. Blankstein R., Budoff M. J., Shaw L. J., et al. Predictors of coronary heart disease events among asymptomatic persons with low low-density lipoprotein cholesterol MESA(Multi-Ethnic Study of Atherosclerosis). J AM Coll Cardiol. 2011; 58: 364–374.
8. Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vascular Health and Risk Management. 2013; 9: 617–670.
9. Fruchart J. C., Davignon J., Hermans M. P., et al. Residual macrovascular risk in 2013: what have we learned? Cardiovascular Diabetol. 2014; 13: 26–43.
10. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106 (25): 3143–3421.
11. Dallmeier D., Koenig W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a)). Best Pract Res Clin Endicrinol Metab. 2014; 28 (3): 281–294.
12. Дубинина Е. Е., Бурмистров С. О., Ходов Д. А. и др. Окислительная модификация белков сыворотки крови человека, метод ее определения. Вопросы медицинской химии. 1995; 1: 24–26.
Review
For citations:
Kotova Yu.A., Zuykova A.A., Pashkov A.N., Strakhova N.V., Krasnorutskaya O.N. Indicators of oxidative stress, inflammation, and endothelial dysfunction in patients with coronary atherosclerosis while taking statins. Medical alphabet. 2020;(2):29-31. (In Russ.) https://doi.org/10.33667/2078-5631-2020-2-29-31